Dostupnost inovativních léků v Slovenské republice v kontextu současné lékové politiky

The submitted master thesis is purported to accomplish two essential goals. The first one is to provide a detailed overview of the Slovak drug policy which is being executed upon via a process of registration, categorization, and pricing. The second objective is to clarify the situation of a patient’s access to innovative medicine resulting from the Slovak Act 363/2011 and especially from its 1st January 2018 amendment regarding the range and conditions of the drug reimbursement through the public health insurance program. The first part of this master thesis includes a theoretical base which is later utilized by the second and practical part of the thesis. This theoretical base contains descriptions of what a drug, a medicine, a medicine form, and an innovative medicine is, how a medicine is developed and further how the Slovak drug policy works through the processes of registration, categorization and pricing. The theoretical part provides clarification to the uninformed public about how the drug policy is done in the Slovak Republic. The latter practical part of the thesis consists of three most impactful changes born by the amendment to the Act 363/2011 valid as of 1st January 2018 relating to the acceptance of the innovative medicine and its accessibility to patients in Slovakia. These three changes are analyzed in detail resulting in a finding whether each of these changes had an impact on higher accessibility of the innovative medicine to the Slovak patients.